The Gradi App's platform is like Yelp meets Instagram, and users can even receive compensation for their content. by Avery Padilla

When the Houston restaurant industry was in its biggest time of need, two Houstonians stepped up to the plate to deliver a tech tool for the community.

Amid the pandemic, restaurants increasingly rolled out QR code menus to decrease the risk of spreading of germs by eliminating touching physical menus. Houstonians Zachary Dowthitt and Eric Hairston launched Gradi App in February 2021 to help both restaurants and guests access QR Code menus with more ease.

Now, the duo has launched a new approach for its app. The Gradi App, which can be found on the Apple App Store, has branched out to deliver an updated consumer-based model to help Houstonians discover food and drink options from the city’s diverse palate of dining.

Users of the consumer Gradi App can search through photos of menu items to find the best local spots for drinks and food due to proximity and preference. Think Yelp meets Instagram. The app even has an option to book a ride share from Lyft or Uber to the destinations.

“We noticed from menus at restaurants, people are posting their food photos all the time, but menus still don’t have photos" Dowthitt tells InnovationMap. "So, we asked ourselves ‘when was the last time you bought something without seeing it?’ Most people do it at restaurants every day.”

Some of Houston’s most popular spots — Frank’s Pizza, Henke & Pilot, Bovine & Barley, and others — have already been spotlighted on Gradi. Currently, the app has 32 restaurant partners and over 350,000 users.

Dowthitt says he is already thinking of future versions of the app. Users will be able to locate favorite spots, share menus with your friends, search food by items, and post their own photos from each restaurant on the app. Photos will be graded on the app by users, and users can even be compensated for their posts. The most liked photo for each item will be chosen as the featured photo for each restaurant on the app, and users that take these photos will get compensated for their unique content.

Gradi App hopes to have its updated consumer version of the app with search and linked menu options out by December 7. Dowthitt says hee has plans to deliver an upgraded nightlife and happy hour version in the future.

“We’ve eaten with our eyes from the beginning of time,” Dowthitt said. “And we believe in the future, you will see what you order (food or drinks) before you order it…and that is where we come into play.”

. Houstonians Zachary Dowthitt (left) and Eric Hairston launched Gradi App in February 2021Photo courtesy of Avery Padilla

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”